Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

CASC 3.93 -0.09 (-2.24%)
price chart
Cascadian Therapeutics Announces Stockholders and Board of Directors Approve ...
23, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that at a special meeting held on November 18, 2016, stockholders voted to approve a proposal authorizing the board of ...
Cascadian Therapeutics (CASC) Approves 1-for-6 Reverse Stock Split  StreetInsider.com
Cascadian Therapeutics Announces Changes to Board of Directors
SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company's Board of Directors.
Worthwhile Stock-: Cascadian Therapeutics, Inc. (CASC)
USA based company, Cascadian Therapeutics, Inc. (CASC)'s latest closing price distance was -14.66% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 2.61% and 2.56% compared with the 20 Day ...
Citadel Advisors LLC Takes Position in Cascadian Therapeutics, Inc. (NASDAQ ...  BNB Daily (blog)
Cascadian Therapeutics: Worth Much More Than The Present Share Price
Despite misgivings about management, the company possesses a promising clinical candidate in tucatinib that is worth much more than the present valuation.
Cascadian Therapeutics' (CASC) CEO Scott Myers on Q1 2017 Results - Earnings ...
Thank you, Michelle. Good morning and thank you for joining us on this conference call to review and discuss our first quarter 2017 financial results, and provide a corporate update.
Here's Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings.
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in ...
SAN ANTONIO, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that following a recent meeting with the U.S. Food and Drug Administration (FDA) ...
Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA ...  TheStreet.com
Cascadian amends mid-stage study of tucatinib to potentially accelerate ...  Seeking Alpha
Cascadian Therapeutics Inc (USA) (CASC)'s Trend Down, Especially After Forming ...
The chart of Cascadian Therapeutics Inc (USA) (CASC) shows a double bottom with $3.83 target or 4.00 % below today's $3.99 share price.
Cascadian Therapeutics (USA) (CASC) Forms $3.99 Double Bottom, Boothbay Fund ...  Key Gazette
Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the ...
SEATTLE, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company's lead product candidate tucatinib (also known as ONT-380) ...
Analysts See $-0.25 EPS for Cascadian Therapeutics (USA) (CASC), Everspin Tech ...
Analysts expect Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report $-0.25 EPS on August, 14.They anticipate $0.11 EPS change or 30.56% from last quarter's $-0.36 EPS.